Skip to main content
Isomer
  1. Home
  2. Automated
  3. List of product information
  4. MAXIDEX STERILE OPHTHALMIC OINTMENT 0.1% [SIN04153P]

MAXIDEX STERILE OPHTHALMIC OINTMENT 0.1% [SIN04153P]

Active ingredients: MAXIDEX STERILE OPHTHALMIC OINTMENT 0.1%

Last updated 26 October 2025

On this page

Product Info
4.1 Therapeutic Indications
4.2 Posology and method of administration
4.3 Contraindications

Product Info

MAXIDEX STERILE OPHTHALMIC OINTMENT 0.1%

[SIN04153P]

Product information

Active Ingredient and Strength

DEXAMETHASONE - 0.1%

Dosage Form

OINTMENT

Manufacturer and Country

ALCON-COUVREUR NV - BELGIUM

Registration Number

SIN04153P

Licence Holder

NOVARTIS (SINGAPORE) PTE LTD

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

S01BA01

4.1 Therapeutic Indications

MAXIDEX contains dexamethasone, a synthetic corticosteroid.

MAXIDEX is indicated in the management of conditions generally responsive to corticosteroids such as:

  • Certain inflammatory eye conditions of the anterior segment: acute and chronic anterior uveitis, iridocyclitis, iritis and cyclitis, herpes zoster ophthalmicus.

  • Certain external diseases such as phlyctenular kerato-conjunctivitis, nonpurulent conjunctivitis, including vernal, allergic, catarrhal. It is very effective where allergy is a main factor.

  • Recurrent marginal ulceration of toxic or allergic etiology.

  • Thermal and chemical burns.

  • Post-operatively to reduce inflammatory reactions.

4.2 Posology and method of administration

MAXIDEX Ophthalmic Ointment:
Posology
Apply ribbon of ointment into the conjunctival sac(s) up to 4 times daily. When a favorable response is observed, dosage may be reduced gradually to once a day application for several days.

Use in pediatric patients (below 18 years)
The safety and efficacy of MAXIDEX ophthalmic ointment in children have not been established.

Use in patients with hepatic or renal impairment
No studies have been performed in patients with renal or hepatic impairment.

Use in geriatric patients (65 years of age or above)
No overall differences in safety or effectiveness have been observed between elderly and younger patients.

Method of administration
For ocular use only.

To prevent contamination of the tube tip and ointment, care must be taken not to touch the eyelids, surrounding areas or other surfaces with the tube tip. Keep the tube tightly closed when not in use.

If more than one topical ophthalmic product is being used, the products must be administered at least 5 minutes apart. Eye ointments should be administered last.

4.3 Contraindications

  • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.

  • Acute untreated bacterial infections which like other diseases caused by micro-organisms, may be masked or enhanced by the presence of the steroid.

  • Herpes simplex keratitis

  • Vaccinia, varicella, and other viral infections of cornea or conjunctiva.

  • Fungal disease of ocular structures or untreated parasitic eye infections.

  • Mycobacterial ocular infections